Document Detail


A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor.
MedLine Citation:
PMID:  20554517     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Met, the tyrosine kinase receptor for the hepatocyte growth factor is a prominent regulator of cancer cell invasiveness and has emerged as a promising therapeutic target. Binding of the anti-Met monoclonal antibody DN30 to its epitope induces the proteolytic cleavage of Met, thereby impairing the invasive growth of tumors. The molecular mechanism controlling this therapeutic shedding process has so far been unknown. Here, we report that A Disintegrin And Metalloproteinase (ADAM)-10, but not ADAM-17, is required for DN30-induced Met shedding. Knockdown of ADAM-10 in different tumor cell lines or abrogation of its proteolytic activity by natural or synthetic inhibitors abolished Met down-regulation on the cell surface as well as reduction of Met activation. Moreover, hepatocyte growth factor-induced tumor cell migration and invasion were impaired upon ADAM-10 knockdown. Thus, the therapeutic effect of DN30 involves ADAM-10-dependent Met shedding, linking for the first time a specific metalloprotease to target therapy against a receptor tyrosine kinase.
Authors:
Florian Schelter; Julia Kobuch; Marcia L Moss; J David Becherer; Paolo M Comoglio; Carla Boccaccio; Achim Krüger
Related Documents :
2731157 - Cloning efficiency of human melanoma cells is modulated after invasion through a recons...
8008747 - Prognosis of gastric carcinoma revealed by interactions between tumor cells and basemen...
11925127 - Anti-invasive effect of mmi-166, a new selective matrix metalloproteinase inhibitor, in...
10383907 - Expression of matrix metalloproteinase 2 (mmp-2), membrane-type 1 mmp and tissue inhibi...
8171747 - Down regulation of qa gene expression on drug-modified tumor cells.
6239687 - Isolated soluble fractions from the murine b16 melanoma induce primary in vitro syngene...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-06-16
Journal Detail:
Title:  The Journal of biological chemistry     Volume:  285     ISSN:  1083-351X     ISO Abbreviation:  J. Biol. Chem.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-16     Completed Date:  2010-09-30     Revised Date:  2012-06-04    
Medline Journal Info:
Nlm Unique ID:  2985121R     Medline TA:  J Biol Chem     Country:  United States    
Other Details:
Languages:  eng     Pagination:  26335-40     Citation Subset:  IM    
Affiliation:
Institut für Experimentelle Onkologie und Therapieforschung des Klinikums rechts der Isar, Technische Universität München, München, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
ADAM Proteins / physiology*
Amyloid Precursor Protein Secretases / physiology*
Antibodies / pharmacology,  therapeutic use*
Cell Line, Tumor
Hepatocyte Growth Factor / pharmacology
Humans
Membrane Proteins / physiology*
Neoplasm Invasiveness / prevention & control
Neoplasm Metastasis / drug therapy,  prevention & control
Proto-Oncogene Proteins c-met / drug effects,  metabolism*
Receptors, Growth Factor / drug effects,  metabolism*
Chemical
Reg. No./Substance:
0/Antibodies; 0/Membrane Proteins; 0/Receptors, Growth Factor; 67256-21-7/Hepatocyte Growth Factor; EC 2.7.10.1/MET protein, human; EC 2.7.10.1/Proto-Oncogene Proteins c-met; EC 3.4.-/Amyloid Precursor Protein Secretases; EC 3.4.24.-/ADAM Proteins; EC 3.4.24.81/ADAM10 protein, human
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Risk factors and trends in childhood stunting in a district in Western Uganda.
Next Document:  Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human al...